Themis Medicare Ltd Quality Parameters Deteriorate Amid Weak Financial Metrics

Quality Grade Downgrade and Mojo Score Implications

Themis Medicare’s Mojo Score currently stands at 24.0, categorised as a Strong Sell, an intensification from its previous Sell rating as of 14 Aug 2026. This downgrade signals a marked decline in the company’s financial health and operational quality. The shift to a below average quality grade is particularly notable given the company’s standing within a competitive Pharmaceuticals & Biotechnology sector, where peers such as Fredun Pharma and Venus Remedies maintain average quality grades, and others like Ind-Swift Labs and Fermenta Biotec also face below average assessments.

Profitability and Growth Metrics Under Pressure

One of the most alarming indicators is the company’s five-year EBIT growth, which has plummeted by an extraordinary -194.65%. This stark contraction in earnings before interest and tax highlights severe operational challenges and possibly one-off impairments or restructuring costs that have eroded profitability. In contrast, sales growth over the same period remains positive but subdued at 2.39%, indicating that revenue generation has not kept pace with costs or capital deployment.

Return Ratios Reflect Deterioration

Themis Medicare’s average Return on Capital Employed (ROCE) is 11.55%, while Return on Equity (ROE) stands at 12.31%. Although these figures are not alarmingly low in isolation, they fall short of industry benchmarks and have likely declined relative to prior periods, contributing to the downgrade. These returns suggest that the company is generating modest profits relative to the capital invested but is not delivering superior value to shareholders, especially when weighed against the risks posed by its financial structure.

Leverage and Debt Metrics Raise Red Flags

Debt metrics paint a concerning picture. The average Debt to EBITDA ratio is a high 10.13, indicating that the company’s earnings are insufficient to comfortably cover its debt obligations. The EBIT to Interest coverage ratio of 2.84, while above the critical threshold of 1.5, is not robust enough to provide a comfortable buffer against interest expenses, especially in a volatile sector. Net Debt to Equity is moderate at 0.20, but the high Debt to EBITDA ratio suggests that earnings volatility is a significant risk factor.

Operational Efficiency and Capital Utilisation

Sales to Capital Employed ratio averages 0.86, reflecting suboptimal utilisation of capital to generate sales. This inefficiency may be linked to the company’s strategic investments or operational bottlenecks. The tax ratio of 26.76% and dividend payout ratio of 15.43% indicate a conservative approach to shareholder returns, possibly due to the need to preserve cash amid financial pressures.

Shareholding and Market Position

Institutional holding is negligible at 0.02%, signalling limited confidence from large investors. Additionally, pledged shares constitute a significant 43.39%, which could be a concern for minority shareholders regarding promoter commitment and potential liquidity risks. The stock’s price performance has been weak relative to the Sensex, with a 1-month return of -10.32% versus Sensex’s 1.24%, and a 3-year return of -36.58% compared to Sensex’s 19.28%. Although the stock has delivered a 10-year return of 104.17%, this lags substantially behind the Sensex’s 177.10% over the same period.

Comparative Industry Context

Within the Pharmaceuticals & Biotechnology sector, Themis Medicare’s below average quality grade places it behind several peers who maintain average ratings, such as Fredun Pharma, Venus Remedies, and TTK Healthcare. The company’s micro-cap status further accentuates its vulnerability, as smaller market capitalisations often face greater liquidity constraints and higher volatility. The sector itself is characterised by rapid innovation cycles and regulatory challenges, which demand strong operational and financial discipline—areas where Themis Medicare currently underperforms.

Stock Price and Volatility Analysis

The stock closed at ₹104.70 on 17 Aug 2026, marginally up from the previous close of ₹104.00. The 52-week trading range is wide, with a low of ₹65.00 and a high of ₹147.99, reflecting significant price volatility. The day’s trading range between ₹101.20 and ₹105.50 further underscores short-term fluctuations. This volatility, combined with weak fundamentals, suggests heightened risk for investors seeking stable returns.

Implications for Investors and Outlook

The downgrade to a below average quality grade and Strong Sell Mojo Grade signals that Themis Medicare is currently facing fundamental challenges that impair its ability to generate consistent shareholder value. Investors should be cautious given the company’s deteriorating EBIT growth, high leverage, and operational inefficiencies. While the company’s ROE and ROCE are positive, they do not compensate for the risks posed by its debt profile and weak earnings trajectory.

Conclusion: A Cautionary Tale for Micro-Cap Investors

Themis Medicare Ltd’s recent quality grade downgrade from average to below average, coupled with a Strong Sell Mojo Grade, reflects a company grappling with significant operational and financial headwinds. The steep decline in EBIT growth, high debt burden relative to earnings, and subpar capital efficiency are key factors undermining investor confidence. While the company’s stock has shown some resilience year-to-date, its longer-term returns lag behind broader market indices, underscoring the risks inherent in its current profile.

For investors, this signals a need for heightened scrutiny and consideration of alternative opportunities within the Pharmaceuticals & Biotechnology sector or beyond. Themis Medicare’s challenges serve as a reminder that micro-cap stocks, while potentially rewarding, require careful analysis of quality parameters such as profitability consistency, leverage, and capital utilisation to avoid value erosion.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →